# BPC-157: research overview — Advantage Peptides > A literature summary of BPC-157, a stable gastric pentadecapeptide studied for pro-angiogenic, tissue-protective effects. Covers mechanism, animal and human evidence, and cited safety cautions. A stable gastric pentadecapeptide studied largely in animal models for its pro-angiogenic, tissue-protective effects — with human evidence still limited to a handful of small pilot studies. ## The short version BPC-157 (Body Protection Compound 157) is a synthetic, 15-amino-acid peptide based on a partial sequence of a protein found in human gastric juice. In animal studies it has been linked to faster healing of tendons, ligaments, gut tissue and blood vessels, and its best-understood mechanism involves helping the body grow new small blood vessels, a process called **angiogenesis**. Human evidence is very limited. As of a 2025 review, only three small pilot studies have looked at BPC-157 in people, and there are no large, rigorous clinical trials [2]. One of those pilots — a small intravenous safety study in two healthy adults — found it well tolerated with no adverse effects and no changes to standard safety bloodwork, but that is a safety signal in two people, not proof of a benefit [1]. This page describes what has been studied, in which species, and how far that evidence goes. It recommends no dose and gives no medical advice. ## What it is BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22) derived from a partial sequence of the human gastric-juice protein BPC. It is also referenced in the literature under names including Pentadecapeptide BPC 157, PL 14736, and PL-10. Formal pharmacokinetic work in rats and beagle dogs found that BPC-157 follows linear pharmacokinetics but clears from the body very quickly — its elimination half-life is under 30 minutes — with modest bioavailability by intramuscular injection (roughly 14-19% in rats, 45-51% in dogs), and it is broken down rapidly into small peptide fragments that enter normal amino-acid metabolism, then excreted via urine and bile [3]. That short half-life is a structural fact about the molecule, not a claim about any effect. ## How it works BPC-157's repair effects in animal models are most consistently linked to **angiogenesis**, the growth of new blood vessels. The best-characterized pathway is up-regulation and internalization of the VEGFR2 receptor, with downstream activation of the VEGFR2-Akt-eNOS (nitric-oxide) signaling cascade; in laboratory models this increased vessel density and accelerated blood-flow recovery in ischemic muscle, and blocking the cell's internalization machinery blocked the effect, tying the benefit directly to that receptor pathway [4]. Additional mechanisms reported in the literature include the FAK-paxillin complex (involved in cell migration into damaged tissue), sensitization of the growth-hormone receptor in tendon fibroblasts, and modulation of the nitric-oxide system. A 2016 review also positions BPC-157 as a mediator along the brain-gut axis, describing effects on serotonergic and dopaminergic neurotransmitter systems and involvement of the Egr-1, NAB2, FAK-paxillin and JAK-2 pathways [7]. ## What the research shows *Tissue healing in animal models.* In Wistar rats, BPC-157 reduced gastric ulcer area and accelerated ulcer healing, with an ulcer-formation inhibition ratio of 45.7-65.6% at higher doses; intramuscular delivery outperformed intragastric delivery, and treated tissue showed faster rebuilding of the glandular epithelium and granulation tissue [5]. In a separate rat study, BPC-157 accelerated healing of a fully transected Achilles tendon across biomechanical, functional, microscopic and macroscopic measures, and it stimulated tendocyte (tendon-cell) outgrowth directly in a lab dish [6]. *Vascular mechanism.* Using a chick membrane model, a rat hindlimb ischemia model, and human vascular endothelial cells, researchers showed BPC-157 increases VEGFR2 expression and drives the VEGFR2-Akt-eNOS pathway, raising vessel density and speeding blood-flow recovery after induced ischemia [4]. *Human evidence.* A 2025 narrative review states plainly that only three pilot studies have examined BPC-157 in humans and that rigorous, large-scale trials are lacking, recommending BPC-157 be treated as investigational and approached with caution given its regulatory status and unregulated availability [2]. One of those pilots, a small intravenous safety study, gave up to 20 mg to two healthy adults (a 58-year-old man and a 68-year-old woman) and found it well tolerated with no adverse events and no measurable change in cardiac, hepatic, renal, thyroid or glucose biomarkers — a reassuring but very small safety signal, not an efficacy finding [1]. ## Reported effects, cautions & safety People using BPC-157 in research-use communities describe a fairly consistent set of experiences. These reports are **anecdotal, not clinical evidence** — they come from online forums, wellness-clinic write-ups, and narrative reviews quoting such reports, not from controlled human trials, and none of them specify a verified dose. *Reported benefits:* the most common theme is faster-feeling recovery from tendon, ligament and joint injuries — people describe old sprains, tennis elbow or rotator-cuff strain feeling more usable within one to three weeks. Reduced joint stiffness and pain, improved digestive comfort (attributed to BPC-157's origin in a gastric-juice protein), a general sense of reduced inflammation, faster-looking skin and wound healing, and improved sleep or stress tolerance are also described, roughly in that order of frequency. *Reported adverse effects, also anecdotal, not clinical evidence:* injection-site redness, stinging or a small bump is the most common complaint and is usually described as fading within a day. Mild nausea or stomach upset, first-week fatigue, headache, brief dizziness after injecting, transient flushing or warmth, and — rarely — heart palpitations are also reported. *Cited cautions from the literature:* the human evidence base is extremely thin — only a handful of small pilot reports exist, and large controlled trials are lacking, so animal findings should not be read as proven human benefits [1][2]. Much of the foundational research comes from one research group, limiting independent replication [2]. BPC-157 is not an approved drug and is sold through non-regulated channels, so identity and purity of any given product are unverified outside formal studies [2]. Its strong pro-angiogenic activity is a theoretical concern for anyone with an active or suspected cancer, since tumors also depend on new blood-vessel growth [4]. Animal work showing it alters serotonergic and dopaminergic signaling raises a theoretical, mechanism-based concern about combining it with serotonin-affecting medicines [7]. It is also prohibited at all times in competitive sport by the World Anti-Doping Agency, and it has not been studied for safety in pregnancy, breastfeeding, or children. ## Where it fits in recovery & tissue repair BPC-157 is the lead compound on this desk — the single molecule whose angiogenic, cytoprotective mechanism anchors the recovery-edge framework used to organize the other two members. [GLOW](/glow) builds outward from it, combining BPC-157 with a matrix-remodeling copper peptide (GHK-Cu) and a cell-migration peptide (TB-500) into a skin- and tissue-repair blend. [KLOW](/klow) extends that formula further, adding an anti-inflammatory fourth peptide. Reading BPC-157 first clarifies what the other two members are building on top of. See the [comparison page](/compare) for how the three differ in evidence maturity and mechanism. ![BPC-157 research illustration — abstract tissue-repair and angiogenesis motifs in arctic blue](/images/bpc-157.webp) --- Advantage Peptides is a calm, citation-anchored reference desk for tissue-repair research peptides — not a clinic, not a supplier, and not a source of medical advice.